# Evaluation of predicting performance of POSITIVE, PREDICT and VIRSTA score for Infective Endocarditis in patients with Staphylococcus aureus bacteremia

#### Paulette Pinargote, MD<sup>1</sup>; Wilmer Salazar, MD<sup>2</sup>; Ayeesha Katubbadi, MD<sup>1</sup>; Neev Patel, MD<sup>1</sup>; Mohammad Alfred Nobel Bhuiyan, PhD<sup>3</sup>; John Vanchiere, MD, PhD<sup>4</sup>

[1] Department of Medicine, Division of Infectious Diseases, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA [2] Universidad Católica de Santiago de Guayaquil, Ecuador [3] Department of Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA [4] Department of Pediatrics, Division of Infectious Disease Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana.

#### Background

Prompt identification of Infective Endocarditis (IE) in patients with Staphylococcus aureus bacteremia (SAB) is important as delayed diagnosis results in 15-20% increased mortality. Predictive clinical scoring strategies have been developed to optimize the diagnostic process, particularly the use of invasive methods such as Transesophageal Echocardiography(TEE), known to be superior to Transthoracic Echocardiography. However, the eligibility of TEE is challenged by the nature of its invasiveness in critically ill patients and in those with multiple comorbidities.

Three scoring systems have been proposed to predict the risk of IE: VIRSTA, PREDICT and POSITIVE. We compared these scoring strategies in combination with other clinical data to test the hypothesis that inclusion of time to blood culture positivity(TTP) in the scoring strategies might improve the sensitivity and specificity of clinical risk stratification.

VIRSTA Cutoff: ≥3		POSITIVE Cutoff: >4		PREDICT DAY 5 Cutoff: ≥2		
Variables	Points assigned	Variables	Points assigned	Variables	Points assigned	
Cerebral or peripheral emboli	5	TTP < 9 h	5	Permanent Pacemaker	3	
Meningitis	5	TTP 9-11 h	3	Implantable cardioverter defibrillator	2	
Permanent intracardiac device	4	TTP 11-13h	2	Community acquisition	2	
Previous IE	4	Intravenous drug use	3	Healthcare acquisition	1	
Intravenous drug use	4	Vascular phenomena	6	Positive culture after ≥ 72 h	2	
Pre-existing native valve disease	3	Predisposing heart disease	5			
Persistent bacteremia *	3	h <del>r</del> —	1.0			
Vertebral Osteomyelitis	2					
Community or non-nosocomial health care associated acquisition	2					
Severe sepsis or shock	1					
C-reactive protein > 190 mg/L	1					
* Defined as positive follow up blood cult 48hr after initial positive blood culture	ures obtain					

#### Materials and Methods

Adults (≥ 18y) with SAB admitted to Ochsner LSU Health Shreveport in 2020-2021 were retrospectively screened. Patients with polymicrobial bacteremia, with index blood cultures obtained at a different institution and without cardiac imaging were excluded.

In this preliminary analysis, 56 patients (26 with and 30 without IE) were studied.

- IE was defined as patients who met modified Dukes criteria for definite IE.
- The three scores were calculated for each subject.
- TTP, defined as the time from incubation to automated detection, was obtained from the microbiology laboratory.
- <sup>,</sup> Clinical predictors of IE were identified using multivariable logistic regression analysis.

# Results

Table 1: Baseline characteristics

	Total $(n = 56)$			
Age	56		57.4	0.4
Male	· · · · ·	57.69% (15)	63.33% (19)	0.8
BMI	27.64	23.9	31.4	0.3
Race				0.5
Caucasian	37.5% (21)	· · · ·	43.3% (13)	
African American	· · · ·	61.54% (16)	53.3% (16)	
Hispanic	3.57% (2)		3.33% (1)	
Asian	1.79% (1)	3.85% (1)	0	
Comorbidities				
CAD	35.71 (20)	42.3% (11)	30% (9)	0.4
Cirrhosis	7.1% (4)	11.53% (3)	3.33% (1)	0.
CKD	32.1% (18)	× /	26.67% (8)	0.5
Connective tissue disorder	8.9% (5)	· · · ·	6.67% (2)	0.8
COPD	25% (14)	. ,	23.33% (7)	
CHF	42.9% (24)		36.67% (11)	0.4
Dementia	8.9% (5)		3.33% (1)	0.2
Diabetes	50% (28)	<pre></pre>	56.67% (17)	0.4
HIV Solid Terror of	3.6% (2)	· · ·	3.33% (1)	
Solid Tumor	14.3% (8)		13.33% (4)	0.00
Hematopoietic malignancy	5.4% (3)	0	10% (3)	0.28
Stroke	21.4% (12)		16.67% (5)	0.5
Obesity	33.9% (19)	. ,	43.3% (13)	0.1
Other	23.2% (13)		33.33% (10)	0.
Charslon Comorbidity Index	4		4	0.4
Hemodialysis on admission	19.6% (11)	. ,	13.33% (4)	0.3
Immunocompromised	39.29% (22)	, ,	30% (9)	0.1
Presentation with acute cardio/cerebro vascular accident	17.9% (10)	30.76% (8)	6.67% (2)	0.045
Site of infection	1 700/ (1)	0	0	0.0
Endophthalmitis	1.79% (1)		0	0.9
Osteomyelitis	8.9% (5)		10% (3)	0.15
Septic arthritis	7.1% (4)		13.33% (4)	0.15
Epidural abscess	3.6% (2)		0	0.4
Meningitis	1.8% (1)	. ,	0	0.9
Cellulitis	14.3% (8)	. ,	20% (6)	0.3
Pneumonia	16.1% (9)	. ,	23.33% (7)	0.2
Skin and soft tissue infections	32.1% (18)	. ,	16.67% (5)	0.0
Other (none apparent)	21.4% (12)	15.38% (4)	26.67% (8)	0.4
Predisposing condition	12.50(-7)	10.20/ (5)	( (70/ (2))	0.2
IV drug use	12.5% (7)	. ,	6.67% (2)	0.3
Cardiac device	8.9% (5)	. ,	13.33% (4)	0.4
Pacemaker	3.57% (2)	· · · ·	3.33% (1) 13.33% (4)	0.1
AICD	7.1% (4)		13.33% (4)	0.1
Type of valve Bioprosthetic heart valve	10.7% (6)		3.33% (1) 3.33% (1)	0.1
Bioprosthetic heart valve	7.1% (4)		3.33% (1)	0.
Mechanical heart valve	3.6% (2) 5.4% (3)		0	0.4
History of repaired native valve	5.4% (3)	. ,	6.67% (2)	0.0
Previous Endocarditis Procedure or Investive surgery $\leq 30$ days	1.79% (1)	. ,	0	0.9
Procedure or Invasive surgery $\leq 30$ days Osteomyelitis	32.1% (18) 8 9% (5)	. ,	33.33% (10)	
Osteomyelitis Sentic arthritis	8.9% (5) 7.1% (4)		10% (3) 13.33% (4)	0.1
Septic arthritis Central lines	7.1% (4) 23.2% (13)		13.33% (4) 23.33% (7)	0.1
AVF	23.2% (13) 19.6% (11)	· · ·	23.33% (7) 13.33% (4)	0.3
	19.6% (11) 25% (14)	· · ·	13.33% (4) 33.33% (10)	0.3
None apparent Source (Endovascular)	· · · · ·	15.38% (4) 76.92% (20)	43.3% (10)	0.2
Source (Endovascular) SAB onset	J0.7% (JJ)	10.7270 (20)	<del>т</del> Ј.Ј70 (13)	0.0
Community	35.71% (20)	26.9% (7)	43.3% (13)	0.2
Healthcare	39.29% (22)	. ,	43.3% (13) 30% (9)	
Nosocomial	25% (14)		26.67% (8)	
PITT bacteremia score	2370 (14)	23.08% (0)	20.0770 (0)	0.8
MSSA (organism isolated)	_	57.69% (15)	5 66/67% (20)	0.8
Time to blood culture positivity (hours)	10.65	· · · ·	11	0.0
Duration of bacteremia (days)	5.2	9.03 5.65	3.7	0.1
Persistent bacteremia (272 hours)		61.54% (16)	56.67% (17)	0.0
TTE	100% (56)	· · · ·	100% (30)	0.9
TEE	· · · ·	69.23% (18)	56.67% (17)	0.4
CTA/Cardiac MRI	12.5% (30)		3.33% (1)	0.4
ID consult	71.4% (40)	· · · ·	53.3% (1) 53.3% (16)	0.0
Mortality	/1.7/0 (40)	/2.JI (24)	55.570 (10)	0.00
In hospital	19.6% (11)	19.2% (5)	20% (6)	
in nospital		. ,		
30 day	17.9% (10)	26.92% (7)	10% (3)	0.1

	Sensitivity %	Specificity % (95%		NPV % (95%			Accuracy % (95%	
	(95% CI)	CI)	PPV % (95% CI)	CI)	LR+ (95% CI)	LR- (95% CI)	CI)	AUC
	88.46 (76.18-		50 (35.55-	70 (41.60-	1.154 (0.87-	0.495 (-0.12-	53.57 (40.51-	
VIRSTA	100)	23.33 (8.2-38.47)	64.45)	98.40)	1.43)	1.11)	66.63)	0.732
	76.92 (60.73-		48.78 (33.48-	60 (35.21-	1.099 (0.75-	0.76 (0.08-	51.79 ( 38.70-	
PREDICT	93.12)	30 (13.60-46.40)	64.08)	84.79)	1.45)	1.45)	64.87)	0.547
	69.23 (51.49-		62.069 (44.41-	70.37 (53.15-	1.888 (0.88-	0.4858 (0.18-	68.33 (53.67-	
POSITIVE	86.97)	63.33 (46.09-80.58)	79.73)	87.59)	2.89)	0.80)	78.47)	0.773
	80.77 (65.62-		50 (34.88-	64.29 (39.19-	1.15 (0.81-	0.641 (0.03-	53.57 (40.51-	
TTP ≤13	95.92)	30 (13.60-46.40)	65.12)	89.38)	1.50)	1.26)	66.63)	0.58
VIRSTA +	96.15 (88.76-		48.08 (34.50-	75 (32.57-	1.07 (0.92-	0.38 (-0.46-		
TTP ≤13	100)	10 (0-20.74)	61.66)	100%)	1.22)	1.23)	50 (36.90-63.10)	
PREDICT +	88.46 (76.18-		46 (32.19-		0.98 (0.8-	1.15 (-0.6-	46.43 (33.37-	
TTP ≤13	100)	10 (0-20.74)	59.81)	50 (9.99-90)	1.16)	2.90)	59.49)	

# Results

• The demographic, baseline characteristics and mode of presentation, was no different in both groups based on analysis of >50 factors (Table 1)

The mean TTP for subjects with and without IE were no different (9.65h vs 11h, p=0.12)


• TTP≤13h as an independent variable was found to be sensitive but not specific.


• VIRSTA was found to be the most sensitive scoring method. POSITIVE, which includes TTP as a component, was the most accurate, but least sensitive method.

• Addition of TTP≤13h to VIRSTA and PREDICT increased sensitivity but lowered specificity.

Table 2: Predicting Performance of Clinical scores and Time to Blood Culture Positivity

Figure 1: Receiver Operating Characteristic Curves of VIRSTA, PREDICT, POSITIVE scores







## Conclusions

- While the sensitivity of scoring strategies is acceptable, none of the proposed methods has adequate specificity.
- Inclusion of TTP increases the sensitivity of the scores
- Larger studies are needed for the development of a highly specific and accurate scoring method that includes classic risk factors and TTP.

## References

- 1. Heriot G.S., Tong S.Y.C., Cheng A.C., Liew D. What risk of endocarditis is low enough to justify the omission of transoesophageal echocardiography in Staphylococcus aureus bacteraemia? A narrative review. Clin. Microbiol. Infect. 2018;24:1251-1256. doi: 10.1016/i.cmi.2018.03.027.
- 2. Reynolds HR, Jagen MA, Tunick PA, Kronzon I. Sensitivity of transthoracic versus transesophageal echocardiography for the detection of native valve vegetations in the modern era. J Am Soc Echocardiogr. 2003 Jan;16(1):67-70. doi: 10.1067/mje.2003.43. PMID: 12514637.
- 3. Catherine Liu, Arnold Bayer, Sara E. Cosgrove, Robert S. Daum, Scott K. Fridkin, Rachel J. Gorwitz, Sheldon L Kaplan, Adolf W. Karchmer, Donald P. Levine, Barbara E. Murray, Michael J. Rybak, David A. Talan, Henry F. Chambers, Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children, Clinical Infectious Diseases, Volume 52, Issue 3, 1 February 2011, Pages e18–e55,
- 4. Tubiana S, Duval X, Alla F, Selton-Suty C, Tattevin P, Delahaye F, Piroth L, Chirouze C, Lavigne JP, Erpelding ML, Hoen B, Vandenesch F, lung B, Le Moing V; VIRSTA/AEPEI Study Group. The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia. J Infect. 2016 May;72(5):544-53. doi: 10.1016/j.jinf.2016.02.003. Epub 2016 Feb 22. PMID: 26916042.
- 5. Palraj BR, Baddour LM, Hess EP, Steckelberg JM, Wilson WR, Lahr BD, Sohail MR. Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT): Scoring System to Guide Use of Echocardiography in the Management of Staphylococcus aureus Bacteremia. Clin Infect Dis. 2015 Jul 1;61(1):18-28. doi: 10.1093/cid/civ235. Epub 2015 Mar 25. PMID: 25810284
- 6. Kahn F, Resman F, Bergmark S, Filiptsev P, Nilson B, Gilje P, Rasmussen M. Time to blood culture positivity in Staphylococcus aureus bacteraemia to determine risk of infective endocarditis. Clin Microbiol Infect. 2021 Sep;27(9):1345.e7-1345.e12. doi: 10.1016/j.cmi.2020.11.007. Epub 2020 Nov 13. PMID: 33197608. . Friedman ND, Kave KS, Stout JE, et al. . Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791-7.

Corresponding author: Paulette Pinargote, MD. Contact: pmp004@lsuhs.edu

